Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 29 Dec 2015 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Tata India Pharma & Healthcare Fund |
|---|---|
| 29 Dec 2015 | ₹100.00 |
| 17 Nov 2016 | ₹88.24 |
| 07 Oct 2017 | ₹85.02 |
| 27 Aug 2018 | ₹94.57 |
| 17 Jul 2019 | ₹88.97 |
| 05 Jun 2020 | ₹113.14 |
| 25 Apr 2021 | ₹158.33 |
| 14 Mar 2022 | ₹168.67 |
| 01 Feb 2023 | ₹161.63 |
| 22 Dec 2023 | ₹219.78 |
| 10 Nov 2024 | ₹303.81 |
| 30 Sep 2025 | ₹298.93 |
| 20 Aug 2026 | ₹322.75 |
| Metric | Tata · Regular · IDCW NAV ₹32.39 Very High risk ★★★★★ | Category median Sectoral/ Thematic · 248 funds |
|---|---|---|
| +3.98% | +3.54% | |
| +17.15% | +11.47% | |
| +12.93% | +9.70% | |
| +12.92% | +10.32% | |
| +11.64% | +9.15% | |
| +15.94% | — | |
| +16.31% | +12.10% | |
| +16.98% | +10.32% | |
| +12.24% | +8.80% | |
| Risk | ||
| 13.41% | 15.91% | |
| 0.79 | 0.25 | |
| 1.11 | 0.32 | |
| -21.94% | -26.14% | |
| Nifty 500 | — | |
| +6.76% | -0.04% | |
| 0.80 | 0.98 | |
| 108.2% | 98.3% | |
| 77.5% | 101.5% | |
| 2.32% | 2.38% | |
| ₹1,541Cr | ₹1,160Cr | |
| 0.25% | — | |
| None | — | |
| ₹100 | — | |
| ₹5.00K | — | |
| 27% | 42% | |
| Rajat Srivastava · 1.9y | — | |
| 29 Dec 2015 | — | |
| 34 | — | |
| 52.0% | — | |
| 2.6% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.